Mon panier

Biotinylated Cynomolgus VEGF-D Protein, His,Avitag™

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
VED-C82E3-25ug
$350.00
VED-C82E3-200ug (100ug X 2)
$1380.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    FIGF, VEGFD

  • Source

    Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (VED-C82E3) is expressed from human 293 cells (HEK293). It contains AA Phe 93 - Ser 201 (Accession # G7Q297).

    Predicted N-terminus: Phe 93

    Request for sequence
  • Molecular Characterization

    VEGF-D Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 19.7 kDa. The protein migrates as 27-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    VEGF-D SDS-PAGE

    Biotinylated Cynomolgus VEGF-D Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     VEGF-D ELISA

    Immobilized Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (Cat. No. VED-C82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with a linear range of 0.005-0.156 μg/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     VEGF-D SPR

    Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) captured on Protein A Chip can bind Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (Cat. No. VED-C82E3) with an affinity constant of 1.19 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-CELL BASE

     VEGF-D CELL

    Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (Cat. No. VED-C82E3) induced NFAT-Luc-VEGF R2 Reporter activity in HEK293 cells. The EC50 value of this effect is 1.42 μg/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Vascular endothelial growth factor D

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    2 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte